Literature DB >> 15717292

Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report.

Hamid Mostafavi Abdolmaleky1, Kuang-hung Cheng, Andrea Russo, Cassandra L Smith, Stephen V Faraone, Marsha Wilcox, Rahim Shafa, Stephen J Glatt, Giang Nguyen, Joe F Ponte, Sam Thiagalingam, Ming T Tsuang.   

Abstract

DNA methylation changes could provide a mechanism for DNA plasticity and dynamism for short-term adaptation, enabling a type of cell memory to register cellular history under different environmental conditions. Some environmental insults may also result in pathological methylation with corresponding alteration of gene expression patterns. Evidence from several studies has suggested that in schizophrenia and bipolar disorder, mRNA of the reelin gene (RELN), which encodes a protein necessary for neuronal migration, axonal branching, synaptogenesis, and cell signaling, is severely reduced in post-mortem brains. Therefore, we investigated the methylation status of the RELN promoter region in schizophrenic patients and normal controls as a potential mechanism for down regulation of its expression. Ten post-mortem frontal lobe brain samples from male schizophrenic patients and normal controls were obtained from the Harvard Brain Tissue Resources Center. DNA was extracted using a standard phenol-chloroform DNA extraction protocol. To evaluate differences between patients and controls, we applied methylation specific PCR (MSP) using primers localized to CpG islands flanking a potential cyclic AMP response element (CRE) and a stimulating protein-1 (SP1) binding site located in the promoter region. For each sample, DNA extraction, bisulfite treatment, and MSP were independently repeated at least four times to accurately determine the methylation status of the target region. Forty-three PCR trials were performed on the test and control samples. MSP analysis of the RELN promoter revealed an unmethylated signal in all reactions (43 of 43) using DNA from the frontal brain tissue, derived from either the schizophrenic patients or normal controls indicating that this region of the RELN promoter is predominantly unmethylated. However, we observed a distinct methylated signal in 73% of the trials (16 of 22) in schizophrenic patients compared with 24% (5 of 21) of controls. Thus, the hypermethylation of the CpG islands flanking a CRE and SP1 binding site observed at a significantly higher level (t = -5.07, P = 0.001) may provide a mechanism for the decreased RELN expression, frequently observed in post-mortem brains of schizophrenic patients. We also found an inverse relationship between the level of DNA methylation using MSP analysis and the expression of the RELN gene using semi-quantitative RT-PCR. Despite the small sample size, these studies indicate that promoter hypermethylation of the RELN gene could be a significant contributor in effecting epigenetic alterations and provides a molecular basis for the RELN gene hypoactivity in schizophrenia. Further studies with a larger sample set would be required to validate these preliminary observations. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15717292     DOI: 10.1002/ajmg.b.30140

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  141 in total

1.  DNA methyltransferases1 (DNMT1) and 3a (DNMT3a) colocalize with GAD67-positive neurons in the GAD67-GFP mouse brain.

Authors:  Bashkim Kadriu; Alessandro Guidotti; Ying Chen; Dennis R Grayson
Journal:  J Comp Neurol       Date:  2012-06-15       Impact factor: 3.215

2.  Epigenetics in the human brain.

Authors:  Isaac Houston; Cyril J Peter; Amanda Mitchell; Juerg Straubhaar; Evgeny Rogaev; Schahram Akbarian
Journal:  Neuropsychopharmacology       Date:  2012-05-30       Impact factor: 7.853

Review 3.  The environment and susceptibility to schizophrenia.

Authors:  Alan S Brown
Journal:  Prog Neurobiol       Date:  2010-10-16       Impact factor: 11.685

Review 4.  Epigenetic GABAergic targets in schizophrenia and bipolar disorder.

Authors:  A Guidotti; J Auta; Y Chen; J M Davis; E Dong; D P Gavin; D R Grayson; F Matrisciano; G Pinna; R Satta; R P Sharma; L Tremolizzo; P Tueting
Journal:  Neuropharmacology       Date:  2010-11-11       Impact factor: 5.250

5.  Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia.

Authors:  E Dong; R C Agis-Balboa; M V Simonini; D R Grayson; E Costa; A Guidotti
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-19       Impact factor: 11.205

6.  Nicotine restores Wt-like levels of reelin and GAD67 gene expression in brain of heterozygous reeler mice.

Authors:  Emilia Romano; Andrea Fuso; Giovanni Laviola
Journal:  Neurotox Res       Date:  2013-02-06       Impact factor: 3.911

7.  The Neurobiological Basis for Social Affiliation in Autism Spectrum Disorder and Schizophrenia.

Authors:  Amanda Crider; Anilkumar Pillai
Journal:  Curr Behav Neurosci Rep       Date:  2016-04-16

Review 8.  Epigenetics and psychiatry.

Authors:  Melissa Mahgoub; Lisa M Monteggia
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 9.  Pharmacology of epigenetics in brain disorders.

Authors:  Pritika Narayan; Mike Dragunow
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

Review 10.  Epigenetic regulation in human brain-focus on histone lysine methylation.

Authors:  Schahram Akbarian; Hsien-Sung Huang
Journal:  Biol Psychiatry       Date:  2008-09-24       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.